B cell depletion in autoimmune rheumatic diseases

Autoimmunity Reviews

Volumn 4, Issue 7, 2005, Pages 436-441

  Pitashny, Milena ^a,b   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anti CD20; Autoimmune diseases; B cell depletion; Rituximab

Indexed keywords

ANTIRHEUMATIC AGENT; CD20 ANTIGEN; CELL MARKER; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL TRIAL; COUGHING; DERMATOMYOSITIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOPATHOLOGY; IMMUNOPHARMACOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; POLYNEUROPATHY; PRURITUS; RASH; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; LYMPHOPENIA; RHEUMATIC DISEASES;

EID: 24044439146     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2005.03.002     Document Type: Review

References (21)

1. Maloney David G, Grillo-López Antonio J, White Christine A, Bodkin David, Schilder Russell J, Neidhart James A, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 90;2188-2195.
2. Shan Daming, Ledbetter Jeffrey A, Oliver W. Press Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 91;1644-52.
3. P. McLaughlin, A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, and M.E. Williams Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 1998 2825 2833
4. G.S. Panayi B cell-directed therapy in rheumatoid arthritis-clinical experience J Rheumatol, Suppl 73 2005 19 24
5. B.L. Kotzin The role of B cells in the pathogenesis of rheumatoid arthritis J Rheumatol, Suppl 73 2005 14 18
6. J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, and D.R. Close Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2004 2572 2581
7. P.P. Sfikakis, J.N. Boletis, S. Lionaki, V. Vigklis, K.G. Fragiadaki, and A. Iniotaki Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial Arthritis Rheum 52 2005 501 513
8. Y. Sherer, A. Gorstein, M.J. Fritzler, and Y. Shoenfeld Autoantibody explosion in systemic lupus erythematosus: more than 100 different autoantibodies found in SLE patients Semin Arthritis Rheum 34 2004 501 537
9. R.J. Looney, J.H. Anolik, D. Campbell, R.E. Felgar, F. Young, and L.J. Arend B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab Arthritis Rheum 50 2004 2580 2589
10. E.R. Ahn, G. Lander, C.J. Bidot, W. Jy, and Y.S. Ahn Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy Am J Hematol 78 2005 127 129
11. S. Perrotta, F. Locatelli, A. La Manna, L. Cennamo, P. De Stefano, and B. Nobili Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus Br J Haematol 116 2002 465 467
12. J.G. Erdozain, G. Ruiz-Irastorza, M.V. Egurbide, and C. Aguirre Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome Haematologica 89 2004 34
13. R. Stasi, A. Pagano, E. Stipa, and S. Amadori Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Blood 98 2001 952 957
14. F. Zaja, I. Iacona, P. Masolini, D. Russo, A. Sperotto, and S. Prosdocimo B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia Haematologica 87 2002 189 195 [Erratum in: Haematologica 2002; 87:336]
15. R.J. Looney B cell-targeted therapy in diseases other than rheumatoid arthritis J Rheumatol, Suppl 73 2005 25 28
16. K.A. Keogh, M.E. Wylam, J.H. Stone, and U. Specks Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis Arthritis Rheum 52 2005 262 268
17. T.D. Levine Rituximab in the treatment of dermatomyositis: an open-label pilot study Arthritis Rheum 52 2005 601 607
18. S.J. Ruegg, P. Fuhr, and A.J. Steck Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg Neurology 63 2004 2178 2179
19. A. Pestronk, J. Florence, T. Miller, R. Choksi, M.T. Al-Lozi, and T.D. Levine Treatment of IgM antibody associated polyneuropathies using rituximab J Neurol Neurosurg Psychiatry 74 2003 485 489
20. N.L. Monson, P.D. Cravens, E.M. Frohman, K. Hawker, and M.K. Racke Effect of rituximab on the peripheral Blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis Arch Neurol 62 2005 258 264
21. M.C. Sneller Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? Arthritis Rheum 52 2005 1 5